DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Four-Week Omeprazole Treatment of Non-Erosive Reflux Disease in a Japanese Population

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-Erosive Reflux Disease

Intervention: Omeprazole (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
AstraZeneca Medical Science Director, MD, Study Director, Affiliation: AstraZeneca

Summary

The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.

Clinical Details

Official title: A Double-Blind, Randomised, Parallel-Group, Multicentre, Phase III Study to Compare the Efficacy of Omeprazole 20mg and 10mg Od for the Four-Week Treatment of Non-Erosive Reflux Disease (NERD) With That of Placebo Od and to Investigate Safety

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: To determine the efficacy of omeoprazole 20mg and omeprazole 10mg by assessment of complete resolution rate of heartburn during the fourth week of treatment.

Secondary outcome: Complete resolution of heartburn during the first and second week of treatment, assessment of sufficient relief rates of heartburn, assessment of nocturnal heartburn, assessment of other GERD symptoms.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who identified their predominant symptom as heartburn and were classifiend as

Grande M or N according to Hoshihara’s modofied version of Los Angeles Classification at esophagogastroduodenoscopy.

Exclusion Criteria:

- Patients with any ongoing gastrointestinal bleeding at the time of

esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study

Locations and Contacts

Asa, Japan

Ota, Japan

Ube, Japan

Kita, Japan

Otsu, Japan

Beppu, Japan

Kyota, Japan

Nanao, Japan

Onoda, Japan

Osaka, Japan

Tokyo, Japan

Meguro, Japan

Minato, Japan

Nagoya, Japan

Chiyoda, Japan

Fujieda, Japan

Fukuoka, Japan

Sapporo, Japan

Kanagawa, Japan

Mizumaki, Japan

Shinjuku, Japan

Kawagucki, Japan

Shinagawa, Japan

yukuhashi, Japan

Kitakyushu, Japan

Mitsukaido, Japan

Additional Information

Starting date: October 2003
Last updated: November 25, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009